Am J Transplant, Volume 17, Suppl 3 Archives - Page 46 of 181 - ATC Abstracts

2017 American Transplant Congress
Potential Living Kidney Donors (LKD) Concerns About Opting Out and Preferences for an 'Alibi'.
K. Yu,¹ C. Thiessen,¹ S. Li,¹ D. Dobosz,¹ J. Gannon,¹ K. Kennedy,² D. Gray,³ A. Mussell,³ P. Reese,³ S. Kulkarni,¹ E. Gordon.²
¹Yale U, New Haven; ²Northwestern U, Chicago; ³U Pennyslvania, Philadelphia
PurposeTo evaluate potential LKDs comfort discussing opting out with their intended recipient (IR) and preferences for alibisMethodsWe conducted a prospective, longitudinal study of potential LKDs…
2017 American Transplant Congress
Impact of Dialysis During the Transplant Admission on Transplant and Post-Transplant Cost of Care.
J. Tao,¹ C. Horstman,¹ W. Bannister,¹ M. Schnitzler,² F. Irwin,¹ A. Bonagura,¹ B. Laihinen.¹
¹Complex Medical Conditions, Optum, UnitedHealth Group, Eden Prairie, MN; ²Surgery, St Louis University, St Louis, MO
This study examines the impact of dialysis during the transplant admission on total cost of transplant and one year post-transplant care for kidney, liver, and…
2017 American Transplant Congress
Biological Interplay Between Circulating HLA-sp Alloreactive Memory B-Cells and Long-Lived Plasma Cells in Kidney Transplant Patients Undergoing Chronic ABMR.
S. Luque,² M. Lúcia,⁴ M. Jarque,² E. Crespo,² E. Melilli,¹ J. Martorell,³ J. Cruzado,^1,2 J. Torras,^1,2 J. Grinyó,^1,2 O. Bestard.^1,2
¹Kidney Transplant Unit, Bellvitge University Hospital, Barcelona, Spain; ²Experimental Nephrology Laboratory, IDIBELL, Barcelona, Spain; ³Immunogenetics Laboratory, Hospital Clínic, Barcelona, Spain; ⁴Transplant Immunology, School of Medicine, Stanford
Alloreactive humoral responses are one of the main causes of immune-mediated allograft injury in kidney transplantation. Different biological compartments are involved in the generation and…
2017 American Transplant Congress
Sirolimus Prolonged Survival After Living Donor Liver Transplantation for HCC Beynd Milan Criteria; Outcome of a Multicenter Prospective Randomized Phase II Trial (ClinicalTrials.gov Identifier: NCT01374750).
K.-W. Lee,¹ S.-H. Kim,² N.-J. Yi,¹ S.-K. Hong,¹ G. Yoon,¹ H. Kim,¹ D. Oh,¹ S.-S. Han,² S.-J. Park,² K.-S. Suh.¹
¹Department of Surgery, Seoul National University, Seoul, Republic of Korea; ²Center for Liver Cancer, National Cancer Center, Goyangsi, Republic of Korea
Background:It is unclear whether the reported benefit of mTORi in LT for HCC is from direct effect of mTOR inhibitors. We aimed to compare directly…
2017 American Transplant Congress
Autophagy Regulates LG3 Maturation and Export in Apoptotic Exosome-Like Vesicles.
D. Beillevaire,^1,2,4 M. Francis,^1,2,4 G. Diane,² B. Éric,^3,4 D. Mélanie,^1,2,4 H. Marie-Josée.^1,2,4
¹CRCHUM, Montréal, Canada; ²Université de Montréal, Montréal, Canada; ³CHUL, Québec, Canada; ⁴CNTRP, Edmonton, Canada
Background: Autoantibodies to apoptotic antigens such as LG3 – a C-terminal fragment of perlecan– are present pre-transplantation and contribute to organ rejection in renal transplant…
2017 American Transplant Congress
Post-Donation Remaining Donor Kidney Function as Measured by CKD-EPI Formula at 2 Years Correlates and Is Predicted by Remaining Donor Kidney Volume.
S. Hussain, A. Diez, A. Khalil, M. Yaqub, D. Mishear, T. Taber, O. Adebiyi, C. Sundaram, W. Goggins, J. Powelson, A. Sharfuddin.
Indiana University School of Medicine, Indianapolis
Aim: The aim of our study was to evaluate whether preserved kidney volume correlates with and can predict donor renal function at 2-years post-donation using…
2017 American Transplant Congress
De Novo Use of Everolimus Reduces Late-Onset Cytomegalovirus Primary Disease Occurring After Antiviral Prophylaxis Discontinuation in Kidney Transplant Recipients.
A. Devresse,¹ V. Avettand-Fenoel,² A. Scemla,³ L. Morin,³ X. Lebreton,³ C. Tinel,³ L. Amrouche,³ L. Lamhaut,⁴ M.-O. Timsit,⁵ J. Zuber,³ C. Legendre,³ D. Anglicheau.³
¹Nephrology Unit, Cliniques Universitaires Saint-Luc, Brussels, Belgium; ²Virology Unit, Hôpital Necker-Enfants Malades, AP-HP, Paris, France; ³Kidney Transplantation and Intensive Care Unit, Hôpital Necker-Enfants Malades, AP-HP, Paris, France; ⁴Anesthesia Unit, Hôpital Necker-Enfants Malades, AP-HP, Paris, France; ⁵Urology Unit, Hôpital Necker-Enfants Malades, AP-HP, Paris, France
Background: Donor (D)+/recipient (R)- serostatus is critically associated with an higher risk of cytomegalovirus (CMV) infection and disease. Antiviral prophylaxis is conventionally used in such…
2017 American Transplant Congress
The Impact of Social Support on Kidney Transplant Listing Decisions: Results from a Discrete Choice Experiment.
K. Ladin,^1,2 J. Emerson,² Z. Butt, E. Gordon, D. Hanto, T. Lavelle.²
¹Occupational Therapy, Tufts University, Medford, MA; ²Public Health and Community Medicine, Tufts University School of Medicine, Boston, MA
Background: Although the Centers for Medicare and Medicaid Services require that social support be used to determine transplant eligibility, guidance is vague and centers vary…
2017 American Transplant Congress
A Prospective Iterative Trial of Carfizomib-Based Desensitization Trial: Initial Comparative Observations.
S. Tremblay,¹ A. Shields,^1,2 R. Alloway,¹ P. Brailey,¹ A. Leino,¹ A. Lichvar,¹ B. Abu Jawdeh,¹ J. Driscoll,¹ A. Girnita,¹ E. Woodle.¹
¹U of Cincinnati, Cincinnati; ²Christ Hospital, Cincinnati
Carfilzomib (CFZ) is a 2nd generation proteasome inhibitor different form bortezomib in that it irreversibly disables 20s and 26s proteasomes.Results from the first 2 phases…
2017 American Transplant Congress
Waitlist Desensitization and the Rate of Deceased Donor Kidney Transplantation After Implementation of the Kidney Allocation System.
E. Huang, S. Jordan, R. Najjar, J. Choi, A. Peng, A. Vo.
Comprehensive Transplant Center, Cedars Sinai Medical Center, Los Angeles, CA
Background:At Cedars Sinai Medical Center (CSMC), candidates with calculated panel reactive antibodies (cPRA) ≥30% (based on unacceptable antigens with MFI≥15,000) are desensitized while awaiting transplant.…